Member Info for cyberbub

I tend to agree that the current SP at 2-3% of a potential award seems too cheap. Of course there is risk, it's not a share for widows and orphans, but at this level there must be substantial upside in PAT, in my view. Especially when the announcement of the claim value is expected in the next few weeks...

GLA NAI etc

We will definitely see a raise in the autumn, everyone knows that. But that's 6 months away. If Elevate has 10,000 paid users by then, then the raise will be at well above 10p IMO.

My understanding is that the payment gateway went live to test it with a handful of paid users and make sure it didn't fall over, they said from their experience of other companies that payment gateways often caused big problems. They said they'd got payments in multiple currencies and it was working fine - I'm very pleased to hear it.

Yes Elevate is not 'quite' ready, but in reality it will never be 100% ready as there will always be new features to add. IMO it's currently fully useful and usable, but the company showed a feature list they wanted to implement in Q1 (ie by the end of this month!) including commenting (killer feature for collaboration) before ramping up the big marketing. We have to trust the management, or else we should sell up and move on.

I'm happy with progress, I would have liked them to have gone faster but given that they have limited cash, they couldn't afford to make expensive mistakes.

And don't forget that Streater and McDonough have many millions of reasons to make Elevate work... Including 1M that IM bought at 28p!

NAI etc

They are clearly wanting to ditch their holding inside the tax year, but that doesn't mean they will leave it until the very last moment. They could easily only have a million or two to go.

I've bought 500k at 2.88p at 10:40, not showing yet. GLA NAI

The FCA will do absolutely nothing as always. Currently they're in a state of chaos, but even when they weren't they would never investigate a minnow like this. I was a holder of Paragon Diamonds 10 years ago, the CEO there was proven to be a naked fraud, releasing fantasy RNSes until the company was suspended/delisted and people lost everything. He even had the cheek afterwards to contact shareholders and ask for further bond funding to try to "resurrect" the company, meeting them in a random motorway pub. Sadly some people were further taken in and lost more money. The CEO then moved to Malta and more recently has bought a mansion in Surrey. What happened to him - absolutely nothing whatsoever - sailed off into the sunset with our money. The chances of a foreign national based in India being prosecuted (or even investigated) for alleged fraud/theft at an overseas-based minnow miner are zero I'm afraid. He'll be enjoying the spoils. Just my view of course.

...RNS from Amati which just reiterates greater investment in unlisted companies but still some AIM investment. So it's not certain that they're dumping their full holding in VRCI, although there's probably a good chance that's the case. I've seen investment funds and pension funds dump shareholdings at the lows many times!

Thanks Brondby. There's a much more recent

Do we have evidence from other shares that Amati are doing a general sell-down? Redemptions etc?

..and 11p for a decent amount as well, not a trivial purchase...

Looking into this one, can anyone please explain:

* They had $7m left at late June (after having received $3m in one-off milestone payments, unwinding a big payables balance, and doing a placing). But annual admin costs are over $8m. So with no other milestone payments or commercial income they would be starting to run short of cash by this month?

* We're not clear whether they have received further milestones, although they have mentioned that some will be due at some point. Does anyone know whether they've been received?

* They say they are getting commercial sales now, but can't recognise the revenue until they get Medicare approval. Seems a bit odd to me - what does a medical body's approval have to do with it - if they've received revenues surely they have to report that in their accounts?

* What about other income from private non-Medicare purchases - is there any guidance or forecast on revenues, or total addressable market?

* Amati last declared just over 5% so they will have to declare again when they go below 5% - the fact that they haven't implies that they're selling the lot but won't declare until their broker has sold the last batch.

Any comments appreciated.

Trump and the Republicans don't give a stuff about carbon intensity. They've already started dismantling clean energy legislation, and branding coal and oil as patriotic. Clean = treason bla bla. So I doubt that any US carbon credits, or grants for low-carbon production, will survive much longer.

But the 'domestic production' aspect is very strong under Trumpism and his trade-war agenda, and I think management should emphasise that a lot more. Plus obviously the generally low costs of production and high profitability.

Or maybe they're keeping the big launch under wraps until a few days before?

Or the big launch is down as a separate event in one of the halls, rather than on the stand?

Edgetrader, can you provide a link to the exhibition programme where the Lysate is missing?

Two chunky 250k+ buys today... Encouraging hopefully...

Foxforks that's a different exhibition to the big launch in Amsterdam?

I find it very hard to believe that Croda and Skinbiotix have been lying on record for months about the Lysate launch in Amsterdam next month?

Thanks dustbin. 20 years from what year?

Can anybody advise on how long the patents on the bacterial formulation last?

Thanks!

So I understand that the £350m for Matrixyl is Croda's sales revenue.

Can anyone adv

All, can anyone clarify that the 'double digit percentage' is based on end-user retail sales revenues? I understand that for Matrixyl these are £350m, let's just say that over a few years the lysate formulation achieved similar retail sales, then SBTX would get a minimum of 10% = £35m at a very high margin? Or is the royalty based on the price that Croda sell the ingredient to cosmetic manufacturers, which will obviously be much lower? Thanks for any info.

Let's hope we see a recovery in the SP in the next couple of weeks. I find it hard to believe that we will exit March without the definitive SPAC agreement being closed...

What does that mean?